News
News

The latest updates from AFAR.

AFAR Experts in the News: Nathaniel David and Judith Campisi in Forbes on UNITY Biotechnology’s research to target senescent cells

Jun 14
2018

AFAR Experts in the News: Nathaniel David and Judith Campisi in Forbes on UNITY Biotechnology’s research to target senescent cells View MoreBACK

On June 5, 2018, Forbes spotlighted AFAR board member Nathaniel David, Ph.D. and 1990 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient Judith Campisi, Ph.D.

A Biotech Entrepreneur Aims To Help Us Stay Young While Growing Old” focuses on UNITY Biotechnology, a startup co-founded by Nathaniel David and Judith Campisi. The mission of UNITY Biotechnology is to extend human healthspan by using biotechnology and medicine to target age-related diseases. UNITY hopes to develop medicines that remove senescent cells, called senolytics.

However, removing senescent cells has not been tested on humans yet. “The problem is you have to take the first baby step to demonstrate it’s possible. That’s what chapter one is: demonstrate in a human being that the elimination of senescent cells takes a heretofore inescapable aspect of aging and can either halt it or reverse it,” Dr. David states.

Dr. Campisi became involved in senescent cell research in the early 1990s. Campisi explains how UNITY’s vision for moving research from the lab into our lives inspired her to join their team: “For a basic scientist, we always dream our basic research is going to do some good, but in fact it almost never happens without a company.”

Both David and Campisi lent their insights on advances in biotechnology and longevity at a panel organized by AFAR in 2017, The Architects of Aging. Watch a video of the panel here.

Read the full article here.


Nathaniel David, Ph.D., is the Co-founder and President of UNITY Biotechnology.
Judith Campisi, Ph.D., is a Professor at the Buck Institute for Research on Aging and a Co-founder of UNITY Biotechnology.





View MoreBACK TO TOP